The abstract is read at the publisher; the summary is JClub's.
Adding decitabine to busulfan-cyclophosphamide conditioning before allogeneic HSCT reduces 2-year relapse incidence in adults with KMT2A-rearranged leukaemia from 29% to 12%.
- Why it matters: Optimal myeloablative conditioning for adult KMT2A-rearranged leukaemia before allogeneic HSCT remains uncertain, with relapse risk driving the need for better regimens.
- What they did: In an open-label, multicentre phase 3 trial in China, 130 patients (14–65 years) were randomized 1:1 to DAC-BuCy versus BuCy, and 2-year cumulative relapse incidence was compared in the intention-to-treat population.
- The result: The 2-year cumulative incidence of relapse was 12% (95% CI 6–22) with DAC-BuCy versus 29% (19–41) with BuCy (hazard ratio 0·41 [0·20–0·87]; p=0·017), with similar grade 3–5 adverse-event patterns and acceptable safety.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.